MacroGenics Inc (NASDAQ:MGNX) reached a new 52-week low on Thursday . The company traded as low as $15.45 and last traded at $16.49, with a volume of 3758 shares traded. The stock had previously closed at $15.67.
A number of equities research analysts recently weighed in on the company. HC Wainwright set a $34.00 price target on MacroGenics and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research upgraded MacroGenics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Tuesday, November 13th. ValuEngine cut MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Finally, BidaskClub upgraded MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, October 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. MacroGenics has a consensus rating of “Buy” and an average price target of $31.00.
The firm has a market cap of $701.50 million, a P/E ratio of -30.39 and a beta of 2.52.
A number of large investors have recently made changes to their positions in MGNX. Sun Life Financial INC acquired a new stake in MacroGenics during the 2nd quarter valued at $168,000. Verition Fund Management LLC acquired a new stake in MacroGenics during the 3rd quarter valued at $202,000. Keybank National Association OH acquired a new stake in MacroGenics during the 3rd quarter valued at $203,000. Hussman Strategic Advisors Inc. acquired a new stake in MacroGenics during the 3rd quarter valued at $214,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of MacroGenics during the 3rd quarter worth $250,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.
WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2018/12/08/macrogenics-mgnx-reaches-new-1-year-low-at-15-45.html.
About MacroGenics (NASDAQ:MGNX)
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.
Featured Story: What is Depreciation?
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.